Truist raised the firm’s price target on Tenet Healthcare (THC) to $190 from $175 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Billions of dollars of Medicaid payments for hospitals delayed, WSJ reports
- Tenet Healthcare: Strong Performance and Growth Potential Justify Buy Rating Despite Lowered Price Target
- Tenet Healthcare price target raised to $189 from $183 at RBC Capital
- Tenet Healthcare price target raised to $230 from $217 at UBS
- Tenet Healthcare price target raised to $180 from $165 at Guggenheim